Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

Table 5

Locoregional recurrence-free survival rate according to postmastectomy radiotherapy.

Feature	𝑁	No PMRT	PMRT	LRR		𝑃 value
				No PMRT	PMRT
Age groups
≤40	33	18	15	5	1	0.13
41–50	62	25	37	4	5	0.53
51–60	5	18	32	3	6	0.62
>60	25	11	14	0	2	0.24
Clinical T
T1	4	2	2	0	0	—
T2	52	26	24	3	0	0.12
T3	48	27	21	8	1	0.015
T4	66	15	51	1	13	0.15
Clinical N
N0	42	20	22	3	2	0.64
N1	95	45	90	7	4	0.15
N2	33	7	26	2	8	0.87
Multiple foci
No	99	50	49	1	7	0.27
Yes	71	22	49	1	7	0.26
Pathologic T
pTx/pTis	14	7	7	2	1	0.29
pT1	26	13	13	0	0	—
pT2	75	39	36	6	3	0.10
pT3	18	7	11	3	2	0.18
pT4	37	6	31	1	9	0.49
Pathologic N
pN0	20	14	6	2	0	0.35
pN1	63	29	34	3	6	0.62
pN2	52	16	36	5	7	0.16
pN3	35	13	22	2	1	0.54
Downstage
No	115	43	72	8	11	0.51
Yes	55	29	26	4	3	0.68
Histology
Ductal invasive	118	55	63	9	10	0.78
Lobular invasive	36	12	24	0	1	0.48
Others	16	5	11	3	3	0.17
Pathologic skin involvement
Absent	136	66	70	11	5	0.061
Present	34	6	28	1	9	0.44
LVI
Absent	101	47	54	8	6	0.32
Present	69	25	44	4	8	0.93
Nuclear grading*
G1	11	6	5	0	0	—
G2	54	26	28	3	0	0.06
G3	80	33	47	7	9	0.86
Ki 67 index
<20	117	53	64	10	11	0.76
≥20	53	19	34	2	3	0.69
ER status
Negative	64	30	34	4	6	0.81
Positive	106	42	64	8	8	0.32
PgR status
Negative	83	40	43	6	7	0.93
Positive	87	32	65	6	7	0.39
Extracapsular extension
Absence	115	52	63	8	5	0.20
Presence	55	20	35	4	9	0.89
NAC regimen
Anthracyclines-based	69	27	42	5	9	0.74
Anthracyclines- and taxanes-based	93	44	49	6	4	0.38
No anthracyclines-based	8	1	7	1	1	0.008
Adjuvant hormonal therapy
No	62	28	34	4	6	0.86
Tamoxifen	75	31	44	5	6	0.71
AIs	33	13	20	3	2	0.32
Total	170	72	98	12	14

∗Some data are missing. LRR: locoregional recurrence; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC: neoadjuvant chemotherapy; AIs: aromatase inhibitors.